The recruitment of Th17 cells via the CCL20/CCR6 axis was associated with development of autoimmune diseases, thereby rendering the CCL20/CCR6 axis a prospective novel target for the management of autoimmune conditions, inclusive of CP/CPPS. This evidence concerns the gene CCR6 and autoimmune disease.